SGMT News

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne USA - English APAC - English APAC - Traditional Chinese

Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program

Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment USA - English APAC - Traditional Chinese APAC - English

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025